Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Production and in Vitro Characterization of Lisinopril-Loaded Nanoparticles for the Treatment of Restenosis in Stented Coronary Arteries Publisher Pubmed



Varshosaz J1, 2 ; Soheili M1, 2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Faculty of Pharmacy, Isfahan Pharmaceutical Sciences Research Center, Isfahan, Iran
  2. 2. Department of Pharmaceutics, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Journal of Microencapsulation Published:2008


Abstract

Lisinopril, an angiotensin converting enzyme (ACE) inhibitor drug, was encapsulated in poly(lactide-co-glicolide) (PLGA) nanoparticles (NP) for site-specific delivery by catheters in prevention of restenosis. NP were prepared by emulsification-diffusion method. The PLGA type, stabilizing agent type and its concentration were studied as process variables. The z-average particle size varied between 265-412 nm. The highest zeta potential was seen in NP prepared with Pluronic F-68. None of the studied variables or their interactions had a significant effect on the particle size while all had main effect on the zeta potential. The highest entrapment efficiency was 93% and all studied variables and their interactions except PLGA type and its interaction with the stabilizer type had significant effects on the loading. Baker-Lonsdale model was the most appropriate model for release of lisinopril from NP. Five per cent PLGA 75 : 25 and 5% Pluronic F-68 showed promising results for 21 days release of lisinopril as an anti-restenotic agent.
Other Related Docs
23. Sorbitan Monopalmitate-Based Proniosomes for Transdermal Delivery of Chlorpheniramine Maleate, Drug Delivery: Journal of Delivery and Targeting of Therapeutic Agents (2005)